MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Oracle Investment Managemen...	50.46K	2023-08-14	0	50.46K	Shares	105.97K
Lazard Asset Management Llc	1.19K	2023-08-15	0	1.19K	Shares	2K
Longbow Finance Sa	0	2023-11-13	166.67K	-166.67K	Shares	0

NASDAQ:INKT

MiNK Therapeutics, Inc.

Last Close

0.95

02/05 20:00

Market Cap

29.11M

Beta: -

Volume Today

37.87K

Avg: 87.89K

PE Ratio

0.21

PFCF: −1.71

Institutional trades

Institutional Ownership

Current holdings institutionals